基本信息
浏览量:37
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
I finished my Ph.D. studies at the Institute of Medical Biochemistry (UFRJ, Brazil) with 5 articles (3 as 1st author), 2 book chapters (both as 1st author), 4 undergraduate students supervised, and 20 scientific dissemination activities organized.
After obtaining my doctorate degree in Jan/2013, I moved to the ULB Center for Diabetes Research (ULB, Belgium) with a postdoctoral scholarship from the Science without Borders Program (CNPq, Brazil). Under the supervision of Prof. Decio Eizirik, I worked on different lines of research:
- Functional characterization of candidate genes for type 1 diabetes at the pancreatic β-cell level: we showed that the genes BACH2 (Marroqui et al., Diabetes 2014), TYK2 (Marroqui et al., Diabetes 2015) and DEXI (Dos Santos et al., Diabetologia 2019) participate in the regulation of pro-apoptotic pathways stimulated in β-cells.
- Comparison between α- and β-cells upon coxsackievirus B infection: we described that α-cells are more resistant to viral infection than β-cells due to a more efficient antiviral response (Marroqui, Lopes, Dos Santos et al., eLife 2015; co-1st author).
- Complement C3: we showed that complement C3 is an essential survival mechanism in β-cells under a proinflammatory attack (Dos Santos* et al., Endocrinology 2017; *corresponding author).
- In collaboration with Dr. Cécile Julier (INSERM, Université Paris Diderot, France), we described mutations in the gene DUT that caused a syndrome with bone marrow failure and diabetes (Dos Santos et al., Diabetes 2017).
- Role of interferon-α (IFNα) in β-cells: we demonstrated that IFNα induces a long-lasting overexpression of MHC class, endoplasmic reticulum stress, inflammation, and β-cell apoptosis (Marroqui, Dos Santos et al., Diabetologia 2017; co-1st author; Coomans de Brachène, Dos Santos et al., Diabetologia 2018; co-1st author). We also described that PDL1 expression in β-cells was regulated by type I and type II IFNs (Colli et al., EBioMedicine 2018).
Towards the end of my postdoctoral training in Brussels, I was awarded the EFSD Albert Renold Travel Fellowship (European Foundation for the Study of Diabetes) to work at the Diabetes Research Unit, led by Prof. Angel Nadal, at the Universidad Miguel Hernández de Elche (UMH, Spain), where I investigated the effects of IFNα on cytosolic Ca2+ oscillations in mouse β-cells (Oct-Dec/17). Upon Prof. Nadal’s invitation, I moved to the Institute of Research, Development, and Innovation in Healthcare Biotechnology in Elche (IDiBE/UMH).
In 2018, I published 2 review articles: one on the effects of metabolism-disrupting chemicals in mitochondria (Marroqui* et al., J Endocrinol. 2018; *as the corresponding author) and the other regarding bisphenol-A (BPA) exposure and diabetes development (Tuduri et al., Front Endocrinol. 2018).
At the Diabetes Research Unit, I have worked/been working on the following projects:
- BPA and its analogs in β-cells: we showed that BPA, BPS, and BPF alter ion channel expression and activity, as well as insulin secretion in β-cells (Martinez-Pinna et al., Diabetologia 2019; Marroqui et al., Chemosphere 2021).
- Development of test methods to identify metabolism-disrupting chemicals with diabetogenic activity in α- and β-cells: First, we demonstrated that a crosstalk among three estrogen receptors, namely ERα, ERβ, and GPER, mediates the pro-apoptotic effect of BPA in β-cells (Babiloni-Chust, Dos Santos et al., Environ Int. 2022; co-1st author). Afterward, we proposed different in vitro test methods to assess cell viability and function in α- and β-cells (Dos Santos et al., Int J Mol Sci. 2022; Dos Santos et al., Int J Mol Sci. 2023).
Lately, I have strengthened my ties with Dr. Laura Marroqui, an Assistant Professor in our research unit. In the last 3 years, we wrote a book chapter discussing the role of type I interferons on β-cells (Marroqui* et al., Int Rev Cell Mol Biol. 2021; *as the corresponding author), showed that BCL-XL protects β-cells from pro-apoptotic insults (Perez-Serna, Dos Santos et al., Int J Mol Sci. 2023; co-1st author) and that deucravacitinib, a selective TYK2 inhibitor, protected β-cells against the effects of proinflammatory cytokines (Dos Santos* et al., bioRxiv 2023; *corresponding author). We also created the Workshop for Juniors Investigators: what is going on in Diabetes research?, which is on its way to the 5th edition.
In summary, I have published 27 articles (14 as 1st author, 3 as corresponding author) and have an h-index of 17 (Mar/23). Moreover, I have presented most of these results as an invited speaker or poster/oral communications at scientific meetings. According to the Expertscape ranking, I ranked 16th (out of 863 eligible researchers) among the top experts in the field Islets of Langerhans in Spain during 2013-2023. I currently work as a Review Editor for the journal Frontiers in Endocrinology, as a Guest Editor for Biomedicines, and as a regular reviewer for several journals.
研究兴趣
论文共 43 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
International Journal of Molecular Sciencesno. 6 (2023): 5657-5657
引用0浏览0引用
0
0
International journal of molecular sciencesno. 6 (2023)
Frontiers in immunology (2023): 1263926
Environment International (2022): 107250-107250
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn